Adaptimmune Therapeutics plc (ADAP)
- Previous Close
1.0100 - Open
1.0300 - Bid 0.9602 x 300
- Ask 0.9972 x 200
- Day's Range
0.9800 - 1.0300 - 52 Week Range
0.4200 - 2.0500 - Volume
834,393 - Avg. Volume
1,801,111 - Market Cap (intraday)
254.748M - Beta (5Y Monthly) 2.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.56
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
www.adaptimmune.comRecent News: ADAP
View MorePerformance Overview: ADAP
Trailing total returns as of 9/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADAP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADAP
View MoreValuation Measures
Market Cap
254.75M
Enterprise Value
87.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.69
Price/Book (mrq)
2.65
Enterprise Value/Revenue
0.62
Enterprise Value/EBITDA
-1.71
Financial Highlights
Profitability and Income Statement
Profit Margin
-51.25%
Return on Assets (ttm)
-15.84%
Return on Equity (ttm)
-65.04%
Revenue (ttm)
141.46M
Net Income Avi to Common (ttm)
-72.5M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
214.79M
Total Debt/Equity (mrq)
49.18%
Levered Free Cash Flow (ttm)
-7.95M